The following disclosure has been added to the original article (Polosukhina et al., 2017). Dr. Arteaga was on a Novartis Advisory Board at the time of publication, but the Board service was unrelated to this study.
Authors: Dina Polosukhina; Harold D Love; Hernan Correa; Zengliu Su; Kimberly B Dahlman; William Pao; Harold L Moses; Carlos L Arteaga; Harold N Lovvorn; Roy Zent; Peter E Clark Journal: Mol Oncol Date: 2017-03-15 Impact factor: 6.603